Antídotos e medicamentos utilizados para tratar intoxicações no Brasil: necessidades, disponibilidade e oportunidades

Antidotos e determinados medicamentos sao essenciais ao tratamento de algumas intoxicacoes e nao podem sofrer falhas no abastecimento, sob o risco de prejudicar a saude e a seguranca da populacao. O objetivo deste trabalho foi avaliar a disponibilidade de antidotos e medicamentos recomendados para o tratamento de intoxicacoes no Brasil. A partir de consensos internacionais, foram selecionados 41 antidotos para analise, todos sem patente em vigencia. Desses, 27 sao registrados, porem 11 estao disponiveis em formas inadequadas ao tratamento de intoxicacoes, restando 16 medicamentos comercialmente disponiveis. Somente um terco dos medicamentos necessarios para o tratamento de intoxicacoes esta incluido na relacao de medicamentos essenciais do pais. Em adicao, e apresentada proposta de suprimento das demandas a um dos antidotos, anticorpo antidigoxina, considerando a capacidade de producao nacional de imunobiologicos. Os resultados demonstram limitacao da assistencia adequada aos pacientes intoxicados no pais e reforcam a necessidade urgente de politicas publicas na area.

[1]  J. Kalil,et al.  Anti-Digoxin Fab Variants Generated by Phage Display , 2013, Molecular Biotechnology.

[2]  D. Jacobsen,et al.  A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae , 2012, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

[3]  R. Gair.  Antidote program in British Columbia. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  V. Abbott,et al.  Access in New Zealand to antidotes for accidental and intentional drug poisonings. , 2012, Journal of primary health care.

[5]  M. Silva,et al.  ECONOMIC EVALUATION OF POISON CENTERS: A SYSTEMATIC REVIEW , 2012, International Journal of Technology Assessment in Health Care.

[6]  V. Cohen,et al.  Antidotes for toxicological emergencies: a practical review. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  D. Spyker,et al.  2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report , 2011, Clinical toxicology.

[8]  T. Galvão,et al.  Padronização das informações toxicológicas no Brasil , 2011 .

[9]  Edgar Hernández-Leiva.  Epidemiología del síndrome coronario agudo y la insuficiencia cardiaca en Latinoamérica , 2011 .

[10]  James A. Swenberg,et al.  Toxicology and Epidemiology: Improving the Science with a Framework for Combining Toxicological and Epidemiological Evidence to Establish Causal Inference , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  N. Buckley,et al.  Oximes for acute organophosphate pesticide poisoning. , 2011, The Cochrane database of systematic reviews.

[12]  Carlos Alberto Silva,et al.  Impact of a poison control center on the length of hospital stay of poisoned patients: retrospective cohort. , 2011, Sao Paulo medical journal = Revista paulista de medicina.

[13]  G. C. Rodgers,et al.  Antidotes and Treatments for Chemical Warfare/Terrorism Agents: An Evidence‐Based Review , 2010, Clinical pharmacology and therapeutics.

[14]  J. Feussner,et al.  Reassessing the efficacy of digitalis: from routine treatment to evidence-based medicine. , 2010, The American journal of the medical sciences.

[15]  K. Wong,et al.  Availability of antidotes for the treatment of acute poisoning in Queensland public hospitals. , 2010, The Australian journal of rural health.

[16]  Silas W Smith.  Drugs and pharmaceuticals: management of intoxication and antidotes , 2010, EXS.

[17]  C. Smollin.  Toxicology: pearls and pitfalls in the use of antidotes. , 2010, Emergency medicine clinics of North America.

[18]  R. Wise,et al.  Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. , 2009, Annals of emergency medicine.

[19]  K. Kehe,et al.  Development of antidotes: problems and strategies. , 2007, Toxicology.

[20]  C. Steffen.  The dilemma of approving antidotes. , 2007, Toxicology.

[21]  J. Brubacher,et al.  Adequacy of antidote stocking in British Columbia hospitals: the 2005 Antidote Stocking Study. , 2006, CJEM.

[22]  D. Roberts,et al.  Antidotes for acute cardenolide (cardiac glycoside) poisoning. , 2006, The Cochrane database of systematic reviews.

[23]  P. Hauptman,et al.  Digoxin use and digoxin toxicity in the post-DIG trial era. , 2006, Journal of cardiac failure.

[24]  C. Morillo,et al.  Congestive heart failure in Latin America: the next epidemic. , 2004, American heart journal.

[25]  J. Bussières,et al.  Availability of antidotes in Quebec hospitals before and after dissemination of guidelines. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[26]  D. Bouros,et al.  Availability of antidotes in hospital pharmacies in Greece. , 2001, Veterinary and human toxicology.

[27]  A. Woolf,et al.  Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. , 2000, Annals of emergency medicine.

[28]  S. Walton,et al.  Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity , 2000, Journal of cardiovascular pharmacology and therapeutics.

[29]  S. Lowenstein,et al.  Insufficient stocking of poisoning antidotes in hospital pharmacies. , 1996, JAMA.

[30]  C. Gadelha.  The production and development of vaccines in Brazil , 1996 .

[31]  T. Wenger,et al.  Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. , 1991, The American journal of cardiology.

[32]  Daniel Marques Mota,et al.  Perfil da mortalidade por intoxicação com medicamentos no Brasil, 1996-2005: retrato de uma década , 2012 .

[33]  Amy F Wolkin,et al.  Using poison center data for national public health surveillance for chemical and poison exposure and associated illness. , 2012, Annals of emergency medicine.

[34]  J. Brubacher,et al.  Antidote stocking in British Columbia hospitals. , 2003, CJEM.

[35]  Nara Azevedo,et al.  Inovao em vacinas no Brasil: experincia recente e constrangimentos estruturais , 2003 .

[36]  J. Bussières,et al.  Antidote availability in Quebec hospital pharmacies: impact of N-acetylcysteine and naloxone consumption. , 2000, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[37]  K. Luomanmäki,et al.  [Calcium channel blocker poisoning]. , 1993, Duodecim; laaketieteellinen aikakauskirja.